Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma
, Hyuk Soo Eun 1,3,†, Sorim Choung 4, Hong Jae Jeon 1,2, Jong Seok Joo 1,2, Sun Hyung Kang 1,3, Eaum Seok Lee 1,3, Seok Hyun Kim 1,3, In Sun Kwon 5, Bon Jeong Ku 1,6,* and Byung Seok Lee 1,3,*Round 1
Reviewer 1 Report
Date: 27-Apr-2023
Title: Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma
Cancers
General comments:
This manuscript describes predictive biomarker for evaluating HCC prognosis and monitoring treatment response in patients with HCC. This research is impressive, however there are some issues need to be addressed. Therefore, I recommend the acceptance of this manuscript on the Cancers after minor revision.
Some specific concerns and suggestions are as follows:
(1) The describe of sample type is inconsistent, the sample type is plasma in Blood sampling, storage, and measuremen, but is serum in whole paper, please make sure what is the ample type used in this study?
(2) The combination of serum ERBB2, NRG4, and MIG6 levels could better predict mortality in patients with HCC than AFP, whether the combination of serum ERBB2, NRG4, MIG6 and AFP levels are more better than the combination of serum ERBB2, NRG4, and MIG6 levels?
(3) In this study, why not choose normal people or preoperative people samples as control groups?
Author Response
On behalf of all the authors, I would like to express our sincere gratitude for your thorough consideration and evaluation of our original article.
Detailed responses to the Editor’s and Reviewers’ comments are included below
(the original referee comments are provided in black color, whereas our answers are given in blue in attached separate document, ‘Response to reviewer comments’).
The appropriate changes made in the revised manuscript have been marked in red text in a separate document, ‘Main manuscript’.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Dr. Woo Sun Rouand colleagues purpose an article where they study the
Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma.
I think this work it is highly potential to bring breakthrough changes in clinical practice and management of patient in the future using ERBB2and NRG4to evaluate prognosis and monitor treatment response in patients with HCC.
In general, the article is well conducted and the findings are well presented. I did not identified any major flaws in the methodology used, no major flaws in the data presented, no misleading or false conclusions. I recommend therefore the article to be accepted in your journal for publication.
moderate English
Author Response
On behalf of all the authors, I would like to express our sincere gratitude for your thorough consideration and evaluation of our original article.
Detailed responses to the Editor’s and Reviewers’ comments are included below
The appropriate changes made in the revised manuscript have been marked in red text in a separate document, ‘Main manuscript’.
Reviewer #2:
We appreciate the reviewer for overall comment about our study. Regarding the issues which the reviewer raised, we revised the manuscript's language, and methodology to better meet the requirements.
